Skip Nav Destination
Issues
15 June 2022
-
Cover Image
Cover Image
The cover shows sections of clinical specimens from osteosarcoma and Ewing sarcoma patients. Immunohistochemical staining with D2-40 antibody shows podoplanin expression on the cellular membrane, which is observed in more than half of osteosarcoma cases. Targeting podoplanin with the humanized neutralizing antibody against podoplanin could be a novel therapeutic strategy for podoplanin-positive osteosarcoma. For details, see the article by Takemoto and colleagues on page 2633 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy
Donna Przepiorka; Robert Q. Le; Alexei Ionan; Ruo-Jing Li; Ying-Hong Wang; Ramadevi Gudi; Soumya Mitra; Jonathon Vallejo; Olanrewaju O. Okusanya; Lian Ma; Yuching Yang; Paresma Patel; Djelila Mezaache; Rakhi Shah; Anamitro Banerjee; Sherita McLamore; Adam N. Maung; Kirsten B. Goldberg; Richard Pazdur; Marc R. Theoret; R. Angelo De Claro
Perspectives
Report of the First International Symposium on NUT Carcinoma
Christopher A. French; Michael L. Cheng; Glenn J. Hanna; Steven G. DuBois; Nicole G. Chau; Christine L. Hann; Simone Storck; Ravi Salgia; Matteo Trucco; Jennifer Tseng; Anastasios Stathis; Richard Piekarz; Ulrich M. Lauer; Christophe Massard; Kelly Bennett; Shodeinde Coker; Ulrike Tontsch-Grunt; Martin L. Sos; Sida Liao; Catherine J. Wu; Kornelia Polyak; Sarina A. Piha-Paul; Geoffrey I. Shapiro
Clinical Trials: Targeted Therapy
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Laura Q.M. Chow; Fabrice Barlesi; Erin M. Bertino; Martin J. van den Bent; Heather A. Wakelee; Patrick Y. Wen; Chao-Hua Chiu; Sergey Orlov; Rita Chiari; Margarita Majem; Mark McKeage; Chong-Jen Yu; Pilar Garrido; Felipe K. Hurtado; Pilar Cazorla Arratia; Yuanbo Song; Fabrice Branle; Michael Shi; Dong-Wan Kim
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
Melissa Johnson; Arkadiusz Z. Dudek; Ammar Sukari; Justin Call; Paul R. Kunk; Karl Lewis; Justin F. Gainor; John Sarantopoulos; Patrice Lee; Adele Golden; Allison Harney; S. Michael Rothenberg; Yuanyuan Zhang; Jonathan W. Goldman
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
C. Mircea S. Tesileanu; Marc Sanson; Wolfgang Wick; Alba A. Brandes; Paul M. Clement; Sara C. Erridge; Michael A. Vogelbaum; Anna K. Nowak; Jean-Francois Baurain; Warren P. Mason; Helen Wheeler; Olivier L. Chinot; Sanjeev Gill; Matthew Griffin; Leland Rogers; Walter Taal; Roberta Rudà; Michael Weller; Catherine McBain; Myra E. van Linde; Kenneth Aldape; Robert B. Jenkins; Johan M. Kros; Pieter Wesseling; Andreas von Deimling; Youri Hoogstrate; Iris de Heer; Peggy N. Atmodimedjo; Hendrikus J. Dubbink; Rutger W.W. Brouwer; Wilfred F.J. van IJcken; Kin Jip Cheung; Vassilis Golfinopoulos; Brigitta G. Baumert; Thierry Gorlia; Pim J. French; Martin J. van den Bent
Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
Hiroto Inaba; Jolieke G. van Oosterwijk; John C. Panetta; Lie Li; Daelynn R. Buelow; James S. Blachly; Sheila Shurtleff; Ching-Hon Pui; Raul C. Ribeiro; Jeffrey E. Rubnitz; Stanley Pounds; Sharyn D. Baker
Clinical Trials: Immunotherapy
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Gontran Verset; Ivan Borbath; Mark Karwal; Chris Verslype; Hans Van Vlierberghe; Adel Kardosh; Vittorina Zagonel; Per Stal; Debashis Sarker; Daniel H. Palmer; Arndt Vogel; Julien Edeline; Stephane Cattan; Masatoshi Kudo; Ann-Lii Cheng; Sadahisa Ogasawara; Bruno Daniele; Stephen L. Chan; Jennifer J. Knox; Shukui Qin; Abby B. Siegel; Michael Chisamore; Ken Hatogai; Anran Wang; Richard S. Finn; Andrew X. Zhu
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Markus W. Löffler; Stefania Gori; Francesco Izzo; Andrea Mayer-Mokler; Paolo A. Ascierto; Alfred Königsrainer; Yuk Ting Ma; Bruno Sangro; Sven Francque; Luisa Vonghia; Alessandro Inno; Antonio Avallone; Jörg Ludwig; Diego Duarte Alcoba; Christian Flohr; Katrin Aslan; Regina Mendrzyk; Heiko Schuster; Marco Borrelli; Danila Valmori; Tanguy Chaumette; Regina Heidenreich; Cécile Gouttefangeas; Greta Forlani; Maria Tagliamonte; Caterina Fusco; Roberta Penta; Mercedes Iñarrairaegui; Ulrike Gnad-Vogt; Carsten Reinhardt; Toni Weinschenk; Roberto S. Accolla; Harpreet Singh-Jasuja; Hans-Georg Rammensee; Luigi Buonaguro
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Lakshmi Nayak; Nathan Standifer; Jorg Dietrich; Jennifer L. Clarke; Gavin P. Dunn; Michael Lim; Timothy Cloughesy; Hui K. Gan; Elizabeth Flagg; Elizabeth George; Sarah Gaffey; Julia Hayden; Christina Holcroft; Patrick Y. Wen; Mary Macri; Andrew J. Park; Toni Ricciardi; Aileen Ryan; Paul Schwarzenberger; Ralph Venhaus; Melissa de los Reyes; Nicholas M. Durham; Todd Creasy; Raymond Y. Huang; Thomas Kaley; David A. Reardon
Precision Medicine and Imaging
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
Kim R.M. Blenman; Michal Marczyk; Thomas Karn; Tao Qing; Xiaotong Li; Vignesh Gunasekharan; Vesal Yaghoobi; Yalai Bai; Eiman Y. Ibrahim; Tristen Park; Andrea Silber; Denise M. Wolf; Emily Reisenbichler; Carsten Denkert; Bruno V. Sinn; Mariya Rozenblit; Julia Foldi; David L. Rimm; Sibylle Loibl; Lajos Pusztai
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Camila Guerrero; Noemi Puig; Maria-Teresa Cedena; Ibai Goicoechea; Cristina Perez; Juan-José Garcés; Cirino Botta; Maria-Jose Calasanz; Norma C. Gutierrez; Maria-Luisa Martin-Ramos; Albert Oriol; Rafael Rios; Miguel-Teodoro Hernandez; Rafael Martinez-Martinez; Joan Bargay; Felipe de Arriba; Luis Palomera; Ana Pilar Gonzalez-Rodriguez; Adrian Mosquera-Orgueira; Marta-Sonia Gonzalez-Perez; Joaquin Martinez-Lopez; Juan-José Lahuerta; Laura Rosiñol; Joan Blade; Maria-Victoria Mateos; Jesus F. San-Miguel; Bruno Paiva; on behalf of the Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA)/Grupo Español de Mieloma (GEM) cooperative study group
Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer
Satoshi Fujii; Daisuke Kotani; Masahiro Hattori; Masato Nishihara; Toshihide Shikanai; Junji Hashimoto; Yuki Hama; Takuya Nishino; Mizuto Suzuki; Ayatoshi Yoshidumi; Makoto Ueno; Yoshito Komatsu; Toshiki Masuishi; Hiroki Hara; Taito Esaki; Yoshiaki Nakamura; Hideaki Bando; Tomoyuki Yamada; Takayuki Yoshino
Translational Cancer Mechanisms and Therapy
Targeting Podoplanin for the Treatment of Osteosarcoma
Ai Takemoto; Satoshi Takagi; Takao Ukaji; Nobuhiko Gyobu; Mamoru Kakino; Miho Takami; Asami Kobayashi; Marie Lebel; Tokuichi Kawaguchi; Minoru Sugawara; Kazue Tsuji-Takayama; Kenji Ichihara; Yuki Funauchi; Keisuke Ae; Seiichi Matsumoto; Yoshiya Sugiura; Kengo Takeuchi; Tetsuo Noda; Ryohei Katayama; Naoya Fujita
AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma
Erin G. Reid; Kelly Shimabukuro; Page Moore; Richard F. Ambinder; Jack D. Bui; Semi Han; Otoniel Martínez-Maza; Dirk P. Dittmer; David Aboulafia; Elizabeth Yu Chiao; Toby Maurer; Robert Baiocchi; Ronald Mitsuyasu; William Wachsman; for the AIDS Malignancy Consortium (AMC)
Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Clare Vesely; Yien Ning Sophia Wong; Alexa Childs; Ayse U. Akarca; Pawan Dhami; Heli Vaikkinen; Lucia Conde; Javier Herrero; Olagunju Ogunbiyi; Amir Gander; Tu Vinh Luong; Chrissie Thirlwell; Martyn Caplin; Christos Toumpanakis; Karl Peggs; Sergio A. Quezada; Teresa Marafioti; Tim Meyer
The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma
Smita Sihag; Samuel C. Nussenzweig; Henry S. Walch; Meier Hsu; Kay See Tan; Sergio De La Torre; Yelena Y. Janjigian; Steven B. Maron; Geoffrey Y. Ku; Laura H. Tang; Pari M. Shah; Abraham Wu; David R. Jones; David B. Solit; Nikolaus Schultz; Karuna Ganesh; Michael F. Berger; Daniela Molena
Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Wai-Tong Ng; Cheuk-Wai Choi; Barton But; Roger K.C. Ngan; Stewart Tung; Ashley C. Cheng; Dora L.W. Kwong; Tai-Xiang Lu; Anthony T.C. Chan; Harry Yiu; Sarah Lee; Frank Wong; Kam-Tong Yuen; Richard J. Chappell; Anne W.M. Lee
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip A. Philip; Ibrahim Azar; Joanne Xiu; Michael J. Hall; Andrew Eugene Hendifar; Emil Lou; Jimmy J. Hwang; Jun Gong; Rebecca Feldman; Michelle Ellis; Phil Stafford; David Spetzler; Moh'd M. Khushman; Davendra Sohal; A. Craig Lockhart; Benjamin A. Weinberg; Wafik S. El-Deiry; John Marshall; Anthony F. Shields; W. Michael Korn
Correction
Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Grainne M. O'Kane; Barbara T. Grünwald; Gun-Ho Jang; Mehdi Masoomian; Sarah Picardo; Robert C. Grant; Robert E. Denroche; Amy Zhang; Yifan Wang; Jessica K. Miller; Bernard Lam; Paul M. Krzyzanowski; Ilinca M. Lungu; John M.S. Bartlett; Melanie Peralta; Foram Vyas; Rama Khokha; James Biagi; Dianne Chadwick; Stephanie Ramotar; Shawn Hutchinson; Anna Dodd; Julie M. Wilson; Faiyaz Notta; George Zogopoulos; Steven Gallinger; Jennifer J. Knox; Sandra E. Fischer
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds